The company will provide DNA sequencing to screen newborns for rare genetic conditions.
Biotchnology company Revvity has expanded its partnership with Genomics England to collaborate on the Generation Study, a research project sequencing the genomes of 100,000 newborns.
Revvity, which already offers DNA extraction services for the project, will provide DNA sequencing services to help screen newborns for rare genetic conditions.
“By working with Revvity as one of our sequencing partners for the Generation Study, we can integrate sequencing alongside extraction, streamlining the process, and generating results more efficiently,” said Genomics England chief medical officer Dr Ellen Thomas.
The ability for Revvity to provide end-to-end services with a localised laboratory facility will support accelerated extraction and sequencing solutions to advance the screening processes for rare conditions.
The plan is to screen newborns for over 200 rare genetic disorders, including conditions such as cystic fibrosis, Barth syndrome, sickle cell disease and hypothyroidism.
The Generation study aims to inform decisions on using whole genome sequencing in newborn screening.
Proactive genome screening could help to identify risks for paediatric-onset conditions sooner, enabling earlier interventions and personalised care.
“It is an honour to enhance our collaboration with Genomics England as we align to expand access to genomic sequencing in England,” said Revvity senior vice president and chief scientific officer Dr Madhuri Hegde.
“Our complete solution and localised lab facility help us deliver timely and reliable sequencing data in support of this critical programme that strengthens newborn health.”
Last month, Revvity entered a partnership with Element Biosciences to advance sequencing-based IVD neonatal testing.
